Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long‐acting injectable vs oral antipsychotics

by | May 20, 2019 | Mental Health, Neurological, Publication

Abstract Authors: Shah A, Xie L, Kariburyo F, Zhang Q, Gore M Introduction: Long-acting injectable (LAI) antipsychotic use may reduce healthcare resource utilization compared with oral antipsychotic use by improving adherence and reducing dosing frequency. Our goal...

Health care resource utilization and costs of California‐Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment

by | May 18, 2019 | Mental Health, Publication

Abstract Authors: Pesa JA, Doshi D, Wang L, Yuce H, Baser O. Objective: To compare all-cause health care utilization and costs between patients with schizophrenia treated with once monthly paliperidone palmitate (PP1M; Invega Sustenna) and atypical oral antipsychotic...

Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics

by | May 16, 2019 | Mental Health, Publication

Abstract Authors: Baser O, Xie L, Pesa J, Durkin M. Objective: This study aimed to compare real world healthcare costs and resource utilization between patients with schizophrenia treated with paliperidone palmitate long-acting injection (PP) and oral atypical...